Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681

Journal of Psychopharmacology

Volumn 26, Issue 8, 2012, Pages 1119-1127

  Te Beek, Erik T ^a   Moerland, Matthijs ^a   De Boer, Peter ^b   Van Nueten, Luc ^b   De Kam, Marieke L ^a   Burggraaf, Jacobus ^a   Cohen, Adam F ^a   Van Gerven, Joop M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antipsychotic drug; dopamine D2 receptor; fast dissociation; JNJ 37822681; pharmacodynamics; pharmacokinetics

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; JNJ 37822681; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; AKATHISIA; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; BODY EQUILIBRIUM; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FATIGUE; FINGER; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SACCADIC EYE MOVEMENT; SMOOTH PURSUIT EYE MOVEMENT; SOMNOLENCE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE; VISUOMOTOR COORDINATION;

ADOLESCENT; ADULT; AROUSAL; BRAIN WAVES; CENTRAL NERVOUS SYSTEM; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; POSTURE; PROLACTIN; PURSUIT, SMOOTH; PYRIDAZINES; SACCADES;

EID: 84864137154     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111415733     Document Type: Article

References (55)

1. 2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic- induced hyperprolactinemia. J Clin Psychiatry. 2010 ; 71: 1131-1137
2. Baloh RW, Sills AW, Kumley WE, Honrubia V. Quantitative measurement of saccade amplitude, duration, and velocity. Neurology. 1975 ; 25: 1065-1070
3. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 ; 154: 672-676
4. Ben Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001 ; 22: 724-763
5. Bittencourt PR, Wade P, Smith AT, Richens A. Benzodiazepines impair smooth pursuit eye movements. Br J Clin Pharmacol. 1983 ; 15: 259-262
6. Bond A, Lader M. Use of analog scales in rating subjective feelings. Br J Med Psychol. 1974 ; 47: 211-218
7. Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984 ; 18: 69S - 72S
8. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998 ; 88: 82-88
9. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008 ; 22: 46-55
10. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007 ; 27: 639-661
11. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 ; 192: 481-483
12. de Borja Goncalves Guerra A, Castel S, Benedito-Silva AA, Calil HM. Neuroendocrine effects of quetiapine in healthy volunteers. Int J Neuropsychopharmacol. 2005 ; 8: 49-57
13. de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A α2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol. 2009 ; 23: 625-632
14. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001 ; 51: 119-132
15. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008 ; 22: 12-19
16. Gijsman HJ, van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol. 1998 ; 18: 289-295
17. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004 ; 64: 2291-2314
18. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002 ; 302: 1129-1134
19. 2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000 ; 25: 161-166
20. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001 ; 158: 360-369
21. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008 ; 172: 199-212
22. 2 antagonist for the treatment of schizophrenia. Eur Neuropsychopharmacol. 2010 ; 20: S502
23. Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, et al. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol. 2010a ; 24: 73-82
24. Liem-Moolenaar M, Te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010b ; 24: 1697-1708
25. Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, et al. Central nervous system effects of the interaction between risperidone (single dose) and the 5HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol. 2011 ; 71: 907-916
26. Meltzer HY. Action of atypical antipsychotics. Am J Psychiatry. 2002 ; 159: 153-154
27. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. Effect of clozapine on human serum prolactin levels. Am J Psychiatry. 1979 ; 136: 1550-1555
28. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 1159-1172
29. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 ; 251: 238-246
30. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004 ; 6: 3-7
31. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005 ; 10: 79-104
32. Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008 ; 18: S108 - S114
33. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 ; 13: 27-35
34. Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry. 2002 ; 63: 12-20
35. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971 ; 10: 181-191
36. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999 ; 35: S67 - S73
37. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet. 1997 ; 350: 490-491
38. Pretorius JL, Phillips M, Langley RW, Szabadi E, Bradshaw CM. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol. 2001 ; 52: 322-326
39. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'?. Clin Neurosci Res. 2003 ; 3: 108-117
40. 2 receptor antagonist, in the treatment of schizophrenia. Eur Neuropsychopharmacol. 2010 ; 20: S484 - S485
41. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 ; 47: 27-38
42. 2 atypical antipsychotics. Am J Psychiatry. 2005 ; 162: 1984-1985
43. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975 ; 72: 4376-4380
44. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 ; 261: 717-719
45. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 ; 3: 123-134
46. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999 ; 156: 876-884
47. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970 ;: 11-19
48. 2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol. 2012 ; 26: 1128-1135
49. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002 ; 159: 133-135
50. van Steveninck AL, Gieschke R, Schoemaker HC, Pieters MS, Kroon JM, Breimer DD, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl). 1993 ; 110: 471-478
51. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991 ; 50: 172-180
52. van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999 ; 13: 10-17
53. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004 ; 65: 57-61
54. Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971 ; 218: 27P - 28P
55. Yeudall LT, Reddon JR, Gill DM, Stefanyk WO. Normative data for the Halstead-Reitan neuropsychological tests stratified by age and sex. J Clin Psychol. 1987 ; 43: 346-367